<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005954</url>
  </required_header>
  <id_info>
    <org_study_id>2114</org_study_id>
    <secondary_id>DUMC-2114-02-12R3</secondary_id>
    <secondary_id>NCI-G00-1798</secondary_id>
    <secondary_id>CDR0000067934</secondary_id>
    <nct_id>NCT00005954</nct_id>
  </id_info>
  <brief_title>Temozolomide in Treating Patients With Brain Metastases</brief_title>
  <official_title>Phase II Treatment of Adults With Brain Metastases With Temodar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who&#xD;
      have brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the activity of temozolomide in patients with brain metastases.&#xD;
&#xD;
        -  Determine the toxicity of this treatment in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to type of primary cancer (lung carcinoma vs&#xD;
      breast carcinoma vs malignant melanoma vs renal cell carcinoma vs colorectal carcinoma vs&#xD;
      other).&#xD;
&#xD;
      Patients receive oral temozolomide daily on days 1-7 and 15-21. Treatment repeats every 28&#xD;
      days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 180 patients (30 per stratum) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Metastatic lesions to the brain&#xD;
&#xD;
               -  Must not require immediate radiotherapy&#xD;
&#xD;
               -  If received prior radiotherapy, must have progressive disease&#xD;
&#xD;
          -  Evaluable disease by CT scan or MRI&#xD;
&#xD;
          -  Neurologically stable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT less than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Blood urea nitrogen less than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent nonmalignant systemic disease&#xD;
&#xD;
          -  No acute infection requiring treatment with IV antibiotics&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No frequent vomiting or medical condition that would preclude oral medication&#xD;
             administration (e.g., partial bowel obstruction, inability to swallow)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors, including epoetin alfa&#xD;
&#xD;
          -  No other concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy, unless evidence of disease progression&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed if nonincreasing dose for at least 1 week prior to&#xD;
             study&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to the brain, unless evidence of disease&#xD;
             progression&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior surgery, unless evidence of disease progression, and&#xD;
             recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry S. Friedman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <name_title>Henry Friedman, MD</name_title>
    <organization>Duke UMC</organization>
  </responsible_party>
  <keyword>adult tumors metastatic to brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

